VISTIN PHARMA ASA: årsregnskap 2017 vs 2016
Grew 20954% on revenue
approved 2018-06-26; registry 2018-07-16; journal 2018 673583
Summary
What changed
Comparing Årsregnskap 2017 with 2016 for VISTIN PHARMA ASA. Revenue 394.8k NOK → 83.12m NOK (+20954.4%). Equity 163.61m NOK → 112.93m NOK.
On the constructive side: revenue rose; cash rose. Pressures included: equity eroded.
Also worth watching: paid-in equity reduced; payroll increased; book investments changed. All figures are taken from the published annual accounts for VISTIN PHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 394.8k NOK to 83.12m NOK (+20954.4% YoY). Calculated
-
↑
Cash rose
Bank deposits 20.20m NOK → 41.37m NOK (+104.7% YoY). Calculated
What deteriorated
-
↓
Equity eroded
Book equity 163.61m NOK → 112.93m NOK (equity ratio 98.8% → 85.2%). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 163.61m NOK → 112.93m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 1 775 NOK → 1.82m NOK (0% → 2% of revenue). Calculated
-
·
Book investments changed
Investment / intangible book value 145.47m NOK → 79.62m NOK. Reported fact